Unlabelled: Several authors reported the superiority of (68)Ga-DOTANOC PET/CT to conventional imaging (CI) for the assessment of neuroendocrine tumors (NET). However, the detection of a higher number of lesions is not necessarily followed by a modification of disease stage or therapeutic approach. The aim of this study was to assess the impact of (68)Ga-DOTANOC PET/CT on the clinical management of NET patients.

Methods: The study included 90 patients with pathologic confirmation of NET, CT performed within a month of (68)Ga-DOTANOC PET/CT, and a follow-up period of at least 1 y. PET/CT results were compared with CI results. As a standard of reference to finally evaluate PET results, clinical and imaging follow-up data were used. To assess the clinical impact of PET findings, all referring physicians were contacted after PET and asked about how patients were managed. Stage or therapy modifications were independently recorded, and the overall impact was evaluated patient by patient if PET results either affected therapy or caused a change in disease stage.

Results: Considering PET/CT and CI concordant cases (47/90 [52.2%]), PET findings affected the therapeutic management in 17 of 47 (36.2%) patients. Although PET did not result in modification of disease stage, (68)Ga-DOTANOC detected a higher lesion number in most patients. PET/CT and CI findings were discordant in 42 of 90 (46.7%) patients: PET resulted in a modification of stage in 12 patients (28.6%) and affected the treatment plan in 32 patients (76.2%). PET and CT were both equivocal in 1 patient (1/90). Considering all cases, (68)Ga-DOTANOC PET/CT affected either stage or therapy in 50 of 90 (55.5%) patients. The most frequent impact on management (27 patients) was the initiation or continuance of peptide receptor radionuclide therapy, followed by the initiation or continuance of somatostatin analog medical treatment (7 patients) and referral to surgery (6 patients). PET prevented unnecessary surgery in 6 patients and excluded from treatment with somatostatin analogs 2 patients with NET lesions that did not express somatostatin receptors. Less frequent impacts on management included the initiation of radiotherapy (1 patient), further diagnostic investigation (1 patient), and liver transplantation (1 patient).

Conclusion: (68)Ga-DOTANOC PET/CT either affected stage or caused a therapy modification in more than half the patients, thus confirming the clinical role of PET in the management of NET.

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.109.071712DOI Listing

Publication Analysis

Top Keywords

68ga-dotanoc pet/ct
24
patients
15
patients pet
12
pet
10
pet/ct clinical
8
clinical impact
8
neuroendocrine tumors
8
pet/ct
8
modification disease
8
disease stage
8

Similar Publications

Introduction: Congenital Hyperinsulinism (CHI) has not been previously studied in Ukraine. We therefore aimed to elucidate the genetics, clinical phenotype, histological subtype, treatment and long-term outcomes of Ukrainian patients with CHI.

Methods: Forty-one patients with CHI were recruited to the Ukrainian national registry between the years 2014-2023.

View Article and Find Full Text PDF

Comparison of Ga-DOTANOC and F-FDOPA PET/CT for Detection of Recurrent or Metastatic Paragangliomas.

Radiol Imaging Cancer

January 2025

From the Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, 200032 Shanghai, China; and Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.

Purpose To evaluate the diagnostic performance of gallium 68 (Ga)-DOTA-NaI3-octreotide (Ga-DOTANOC) and fluorine 18 (F)-fluoro-l-3,4-dihydroxyphenylalanine (F-FDOPA) PET/CT in detecting recurrent or metastatic paragangliomas. Materials and Methods This single-center retrospective study included patients with paragangliomas who underwent both Ga-DOTANOC PET/CT and F-FDOPA PET/CT between August 2021 and December 2023. The diagnostic performance of these two tracers in detecting recurrent or metastatic tumors was compared using several metrics, including sensitivity, negative predictive value, and accuracy.

View Article and Find Full Text PDF

Diagnostic performance of [18 F]FDOPA PET/CT and other tracers in pheochromocytoma: A meta-analysis.

Acad Radiol

September 2024

First Hospital of Shanxi Medical University, Clinical Research Center For Metabolic Diseases Of Shanxi Medical University, Taiyuan, Shanxi 030000, China (Y.R., J.Y.). Electronic address:

Article Synopsis
  • The study evaluates the effectiveness of various PET-CT tracers in diagnosing pheochromocytoma (PHEO), a type of tumor, by analyzing data from multiple medical research databases.
  • It includes a meta-analysis of 16 studies, finding that [18 F]FDOPA PET/CT has the highest sensitivity (97%) and specificity (94%) for PHEO detection, with an impressive diagnostic accuracy of 98.9%.
  • The research concludes that while PET/CT is generally effective for PHEO diagnosis, [18 F]FDOPA is the standout tracer among those evaluated, suggesting a need for further studies on other tracers.
View Article and Find Full Text PDF

Neuroblastoma presenting with multiple muscles and subcutaneous tissue metastases is rarely reported in the literature. We would like to highlight such infrequent occurrences for increasing the clinical acumen of the medical fraternity with an aim to deliver proper therapy to patients.

View Article and Find Full Text PDF

Pituitary carcinoma is a rare entity comprising 0.1-0.2% of all pituitary tumors and presents significant diagnostic and therapeutic challenges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!